Status:

RECRUITING

Advanced HIV Disease During the First Six Months on Antiretroviral Therapy in Zambia

Lead Sponsor:

Boston University

Collaborating Sponsors:

Clinton Health Access Initiative Inc.

Bill and Melinda Gates Foundation

Conditions:

Advanced HIV Disease

Eligibility:

All Genders

18+ years

Brief Summary

In Zambia, an estimated 20% of HIV-positive clients continue to present for first-time antiretroviral therapy (ART) initiation or re-initiation with advanced HIV disease (AHD). The Zambia Ministry of ...

Eligibility Criteria

Inclusion

  • Cohort 1
  • Inclusion
  • ≥18 years old
  • Presenting at a study site clinic for HIV diagnosis or care
  • Not currently on ART (or on ART for up to 1 month if enrolled at next visit after AHD screening)
  • Screened for AHD by clinic, prior to or within 1 month of ART initiation
  • Written informed consent to participate
  • Exclusion
  • Pregnant and/or presenting for antenatal care
  • Too ill at the time of AHD screening and at the next clinic visit to participate in the study
  • Unable to communicate in any of the languages into which the questionnaire has been translated or that is known to the research assistant
  • Cohort 2
  • Inclusion
  • ≥18 years old
  • Living with HIV and screened for AHD at a study site within 12 months of the start of study prospective data collection at that site
  • All inclusion criteria for the full cohort
  • Initiated/re-initiated ART within the past 6 months
  • Returns to the study site for a clinic visit during the study enrollment period
  • Written informed consent to participate
  • Exclusion
  • Pregnant and/or presenting for antenatal care as reported in records
  • All exclusion criteria for the full cohort
  • Too ill at the time of study enrollment visit to participate in the study
  • Unable to communicate in any of the languages into which the questionnaire has been translated or that is known to the research assistant
  • Been on ART \>6 months
  • Cohort 3
  • Inclusion
  • ≥18 years old
  • Living with HIV
  • Admitted for inpatient care related to AHD
  • Initiated or re-initiated ART within the last 6 months
  • Written informed consent to participate
  • Exclusion
  • Pregnant and/or presenting for antenatal care
  • Not physically, mentally, or emotionally able to participate in the study prior to discharge, in the opinion of facility or study staff
  • Unable to communicate in any of the languages into which the questionnaire has been translated or that is known to the research assistant
  • Confined to tuberculosis isolation ward; intensive care unit; or other ward specifically for clients with acute infectious disease.
  • Cohort 4
  • Inclusion
  • Employed by or at the study site for at least 6 months
  • Directly interact with clients presenting with AHD
  • Written informed consent to participate
  • Exclusion
  • None

Exclusion

    Key Trial Info

    Start Date :

    April 22 2025

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ESTIMATED

    End Date :

    June 1 2027

    Estimated Enrollment :

    11800 Patients enrolled

    Trial Details

    Trial ID

    NCT06904456

    Start Date

    April 22 2025

    End Date

    June 1 2027

    Last Update

    May 29 2025

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    CHAI-Zambia

    Lusaka, Zambia